NCT05469100

A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal Function

A Phase 1, Open-Label, Parallel-Cohort, Single-Dose Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of LOXO-292

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 37 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to assess the amount of study drug that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment compared to healthy participants. The study will last up to 9 days, excluding screening.

Conditions

• Healthy
• Renal Insufficiency

Interventions

Type	Name	Description
DRUG	Selpercatinib	Administered orally

Timeline

• Start date: 2018-12-19
• Primary completion: 2019-08-07
• Completion: 2019-08-07
• First posted: 2022-07-21
• Last updated: 2025-09-18
• Results posted: 2025-09-18

Locations

6 sites across 1 country: United States

Regulatory

• FDA-regulated drug study